Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Wheaton, Maryland Clinical Trials

A listing of Wheaton, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (17) clinical trials

Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

This study is a Phase 2, open-label study of the combination of a single dose-level of AZ (Zithromax) plus CQ given weekly as a prophylaxis against CQ-resistant P falciparum in healthy adults. After signing informed consent, subjects will undergo screening procedures between Day -77 to Day -18. If enrolled, subjects ...

Phase

3.1 miles

Learn More »

Surgical Idiopathic Intracranial Hypertension Treatment Trial

After signing the informed consent form, potential subjects will be assessed for eligibility, including eliciting medical and neurologic history, measurement of best-corrected visual acuity, visual field testing, ophthalmoscopy with optic disc edema grading, physical examination, and Optical Coherence Tomography (OCT). Questionnaires will be completed. Blood will be drawn for complete ...

Phase

3.56 miles

Learn More »

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Background Study subjects exposed to gene therapy interventions may be at risk for delayed or long term adverse consequences. The U.S. Food and Drug Administration (FDA) has issued Guidance for Industry: Gene Therapy Clinical Trials Observing Participants for Delayed Adverse Events, which outlines a framework to assess the risk of ...

Phase N/A

3.66 miles

Learn More »

Motivations Expectations and Decision-making of Sickle Cell Patients in Clinical Research

Clinical trials testing potentially curative interventions for sickle cell disease - such as gene therapy (GT) or peripheral blood stem cell transplantation (PBSCT) - have created a novel opportunity for patients with sickle cell disease, for whom standard therapies can only manage but not cure their conditions. But some of ...

Phase N/A

3.66 miles

Learn More »

The Genomic Ascertainment Cohort

The Genomic Ascertainment Cohort (TGAC) will be a large cohort of individuals with sequence data unselected for any specific phenotype. TGAC will enable the study of genetic disease while minimizing the bias of phenotypic ascertainment. TGAC will have a two-tiered system of participation. Tier 1 will be individuals who have ...

Phase N/A

3.66 miles

Learn More »

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Treatment Na(SqrRoot) ve Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton s-Tyrosine Kinase Inhibitor (BTK-I)

This study aims to determine the efficacy of the SHINGRIX varicella zoster virus (VZV) vaccine in chronic lymphocytic leukemia (CLL) patients that are treatment naive or receiving Bruton s-tyrosine kinase inhibitor (BTK-I) therapy. Key Eligibility Criteria: Diagnosis of CLL Cohort 1: Treatment naive CLL patients Cohort 2: Subjects must be ...

Phase

3.66 miles

Learn More »

QUILT-3.017: Study of NEO-201 in Solid Tumors

The experimental drug called NEO-201 (the "study drug") is a monoclonal antibody that is being tested and is not approved for use in the United States by the FDA. The primary purpose of this first in human targeted phase 1 open-label study with NEO-201 in subjects with advanced solid tumors ...

Phase

3.66 miles

Learn More »

Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls

Background Chronic graft-versus-host disease (cGVHD) is a multi-organ severe alloimmune and - autoimmune disorder that occurs after allogeneic hematopoietic stem cell transplantation (HSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased survival. Manifestations of cGVHD in the oral cavity are observed in 45-85% of cGVHD patients ...

Phase N/A

3.66 miles

Learn More »

Combining CRLX101 a Nanoparticle Camptothecin With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Background Enzalutamide is established as first-line hormonal therapy in patients with metastatic castration resistant prostate cancer (mCRPC). However, it is increasingly recognized that acquired resistance to therapy (e.g. AR overexpression, AR-V7) could limit the durability of response to therapy Upregulation of HIF-1Alpha in hypoxic tumor cells provides a mechanism of ...

Phase

3.66 miles

Learn More »

HEPLISAV-B Hepatitis B Vaccine in Treatment Na(SqrRoot) ve Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton s-Tyrosine Kinase Inhibitor (BTK-I)<TAB>

This study aims to determine the HEPLISAV-B hepatitis B vaccine efficacy in chronic lymphocytic leukemia (CLL) patients that are treatment naive or receiving Bruton s-tyrosine kinase inhibitor (BTK-I) therapy. Key Eligibility Criteria: Diagnosis of CLL Cohort 1: Treatment naive CLL patients Cohort 2: Subjects must be receiving ibrutinib monotherapy for ...

Phase

3.66 miles

Learn More »